Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS">Functional cure can be sustained in a proportion of patients with chronic hepatitis B (CHB) who lose hepatitis B surface antigen (HBsAg) after pegylated interferon alpha (Peg-IFN-ɑ)-based treatment. In this study, we aimed to identify biomarkers associated with a durable functional cure and to dissect potential immunological mechanisms.</AbstractText>METHODS: <AbstractText Label="METHODS">Of 257 nucleos(t)ide analogue-suppressed patients with CHB in the ANCHOR study, 80 patients randomly assigned to 96-week Peg-IFN-α-based therapy with 24-week off-treatment follow-up were included in this parallel study. Virologic and immunological biomarkers were examined dynamically. A response was defined as HBsAg loss or hepatitis B surface antibody (HBsAb) appearance at the end of treatment (EOT). Sustained response (SR) or durable functional cure was defined as sustained HBsAg loss with or without the appearance of HBsAb at the end of follow-up (EOF).</AbstractText>RESULTS: <AbstractText Label="RESULTS">Thirty-six (45.0%) out of 80 patients achieved a response at EOT; 58.3% (21/36) of responders maintained SR at EOF. Quantitative hepatitis B core-related antigen (qHBcrAg) and HBsAb at EOT were associated with SR, with AUROCs of 0.697 (0.512-0.882, p = 0.047) and 0.744 (0.573-0.915, p = 0.013), respectively. A combination of HBcrAg <4 log10U/ml and HBsAb >2 log10IU/L at EOT had a positive predictive value of 100% for SR with an AUROC of 0.822 (0.684-0.961, p = 0.001). These patients showed maintained proportions of HBV envelope-specific CD8+T and B cells, a markedly increased proportion of T follicular helper cells after Peg-IFN-ɑ discontinuation, and significantly higher proportions of HBV polymerase-specific CD8+T and CD86+CD19+B cells at EOF.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Lower HBcrAg and higher HBsAb levels at EOT were associated with sustained cellular and humoral immune responses. They can be used to identify patients likely to achieve durable functional cure post Peg-IFN-based therapy.</AbstractText>CLINICALTRIALS: <AbstractText Label="CLINICALTRIALS"/>GOV IDENTIFIER: <AbstractText Label="GOV IDENTIFIER">NCT02327416 LAY SUMMARY: Functional cure can be sustained in a proportion of patients with chronic hepatitis B after pegylated interferon alpha-based treatment. However, predicting who will achieve durable functional cure remains challenging. Herein, we show that low levels of hepatitis B core-related antigen and higher levels of hepatitis B surface antibodies at the end of treatment are linked to immunological responses and are associated with durable functional cure.</AbstractText>

Predictors of Functional Cure of Chronic Hepatitis B Virus Infection: A Long-Term Follow-Up Study

Predictors of sustained functional cure in hepatitis B envelope antigen‐negative patients achieving hepatitis B surface antigen seroclearance with interferon‐alpha–based therapy

Clinical Predictors of Functional Cure in Children 1–6 Years-old with Chronic Hepatitis B

Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure

Functional cure of chronic hepatitis B from the point of view of virology

End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB

Functional Cure for Chronic Hepatitis B: Accessibility, Durability, and Prognosis.

Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A

Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels

Circulating HBsAg-specific B cells are partially rescued in chronically HBV-infected patients with functional cure

Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure

Toward a Functional Cure for Hepatitis B

Hepatitis B surface antigen loss and kinetic in chronic hepatitis B patients during interferon alpha treatment: a hospital-based real-world data analysis

Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.

Hepatitis B surface antigen and functional cure of chronic hepatitis B

Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg‐positive patients with functional cure following PEG‐IFN‐based therapy

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

Reduction in Intrahepatic Cccdna and Integration of HBV in Chronic Hepatitis B Patients with a Functional Cure.

The scientific basis of combination therapy for chronic hepatitis B functional cure

Potent Hepatitis B Surface Antigen Response to Treatment of Hepatitis‐b‐e‐antigen‐positive Chronic Hepatitis B with Α‐interferon Plus a Nucleos(t)ide Analog

Functional cure of chronic hepatitis B:current status and perspectives